Point72 Hong Kong’s Pacific Biosciences PACB Stock Holding History

Point72 Hong Kong’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-39,185	Closed	-$173K	–	2291
2022 Q2	$173K	Buy	+39,185	New	+$238K	0.01%	1022
2022 Q1	–	Sell	-35	Closed	-$1K	–	2206
2021 Q4	$1K	Buy	+35	New	+$845	﹤0.01%	1807
2019 Q3	–	Sell	-6,052	Closed	-$37K	–	1252
2019 Q2	$37K	Buy	+6,052	New	+$42.4K	0.01%	675
2018 Q4	–	Sell	-9,192	Closed	-$50K	–	1126
2018 Q3	$50K	Buy	+9,192	New	+$39.4K	0.02%	465
2018 Q2	–	Sell	-1,127	Closed	-$2K	–	1112
2018 Q1	$2K	Buy	+1,127	New	+$2.93K	﹤0.01%	797
2017 Q4	–	Sell	-277	Closed	-$1K	–	1025
2017 Q3	$1K	Buy	+277	New	+$1.19K	﹤0.01%	717

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Hong Kong's PACB Position: Q3 2022 in Review

Point72 Hong Kong sold out of Pacific Biosciences (PACB) in Q3 2022, closing a stake of 39,185 shares — an estimated $173K sold.

Point72 Hong Kong first reported a position in PACB in Q3 2017 and held it in 6 quarters. The position peaked at $173K in Q2 2022. 226 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

Point72 Hong Kong reported no remaining Pacific Biosciences position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 39,185 Pacific Biosciences shares in Q3 2022, an estimated $173K.
Point72 Hong Kong first reported a position in Pacific Biosciences in Q3 2017 and held it in 6 quarters.
Point72 Hong Kong's Pacific Biosciences position peaked at $173K in Q2 2022.
226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.